Alaunos Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Alaunos Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2017 | $15.90M | Mar 2, 2020 |
| FY2013 | Dec 31, 2013 | $200.0K | Mar 3, 2014 |
| FY2013 | Sep 30, 2013 | $200.0K | Mar 3, 2014 |
| FY2013 | Jun 30, 2013 | $200.0K | Mar 3, 2014 |
| FY2013 | Mar 31, 2013 | $200.0K | Mar 3, 2014 |
| FY2013 | Dec 31, 2012 | $200.0K | Mar 3, 2014 |
| FY2013 | Sep 30, 2012 | $200.0K | Mar 3, 2014 |
| FY2013 | Jun 30, 2012 | $200.0K | Mar 3, 2014 |
| FY2013 | Mar 31, 2012 | $200.0K | Mar 3, 2014 |
| FY2012 | Dec 31, 2011 | $200.0K | Mar 18, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $5.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $398.0K | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $0 | Mar 1, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Mar 5, 2019 |
| FY2018 | Sep 30, 2018 | $0 | Mar 5, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.68M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($35.14M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($37.73M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($78.75M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | ($22.77M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($20.32M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($18.60M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($18.29M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($15.75M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | ($74.00M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.81M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($34.27M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($35.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($77.55M) | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | ($22.77M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($20.32M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($18.61M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($18.66M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($16.04M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | ($13.45M) | Mar 1, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.76M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $8.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $64.94M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $94.87M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $146.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $109.11M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $95.05M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $105.61M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $106.35M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $153.72M | Feb 16, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $692.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $26.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $36.81M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $22.36M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $14.10M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $9.49M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $58.42M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $58.33M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $66.35M | Feb 16, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.06M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $6.31M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $38.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $58.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $123.98M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $95.01M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $85.56M | Mar 1, 2021 |
| FY2020 | Dec 31, 2017 | ($96.81M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($77.30M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2015 | $87.37M | Mar 5, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (2) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (21) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (2) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (21) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 7, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 1, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.09M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $6.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $76.05M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $115.07M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $79.74M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $61.73M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $70.95M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $81.05M | Mar 5, 2019 |
| FY2017 | Dec 31, 2015 | $140.72M | Mar 1, 2018 |